Martin Heidecker

AMR Action Fund thesis

As a microbiologist, venture investor, and executive, Henry Skinner, PhD, MBE, MJur, has spent his career working to overcome the scientific and economic challenges associated with antimicrobial drug development. His cross-disciplinary expertise has been essential to shaping the AMR Action Fund’s investment portfolio and policy priorities, with an emphasis on issues pertaining to R&D, innovative financing, and equitable access. Dr. Skinner is regularly sought out for high-level speaking engagements to discuss the global threat of AMR and is frequently featured in the media, including The New Y

Sector and stage focus

• Seed: Pharmaceuticals, BioTech
• Series A: Pharmaceuticals, BioTech
• general: Boston / New England

Is Martin Heidecker a fit for your round?

Upload your pitch deck and see whether Martin Heidecker appears in your top 20 matches.